Point72 Asset Management
BEAM icon

Point72 Asset Management’s Beam Therapeutics BEAM Stock Holding History

Point72 Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$307K Buy
+12,900
New +$358K ﹤0.01% 3353

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Point72 Asset Management's BEAM Position: Q1 2025 in Review

Point72 Asset Management sold out of Beam Therapeutics (BEAM) in Q1 2025, closing a stake of 193,356 shares — an estimated $4.8M sold.

Point72 Asset Management first reported a position in BEAM in Q2 2020 and held it in 5 quarters. The position peaked at $6.12M in Q3 2020. 237 funds tracked by Wall St. Rank hold BEAM as of Q1 2025.

  • Point72 Asset Management reported no remaining Beam Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Point72 Asset Management sold 193,356 Beam Therapeutics shares in Q1 2025, an estimated $4.8M.
  • Point72 Asset Management first reported a position in Beam Therapeutics in Q2 2020 and held it in 5 quarters.
  • Point72 Asset Management's Beam Therapeutics position peaked at $6.12M in Q3 2020.
  • 237 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.